Marrow Therapeutics raises $173M for bone marrow-targeted therapies
Marrow Therapeutics has raised $173 million for transferrin-receptor drug delivery into bone marrow. Its MAR-101 program targets sickle cell disease and beta thalassemia.

U/DEALS-BU
9 filings logged
The money side of pharma — licensing, M&A, venture rounds, earnings and corporate strategy.
Marrow Therapeutics has raised $173 million for transferrin-receptor drug delivery into bone marrow. Its MAR-101 program targets sickle cell disease and beta thalassemia.
